Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Feb;65(2):347-349.
doi: 10.1111/ijd.17913. Epub 2025 Jun 17.

Long-Term Use of Tralokinumab in Patients With Atopic Dermatitis: A Real-World Multicentric Case Series

Christine Bangert  1 , Barbara Ebner  2 , Barbara Gruber  3 , Damian Meyersburg  4 , Judith Traxler  5
Affiliations

Long-Term Use of Tralokinumab in Patients With Atopic Dermatitis: A Real-World Multicentric Case Series

Christine Bangert et al. Int J Dermatol. 2026 Feb.
No abstract available

Keywords: atopic dermatitis; case series; long‐term effectiveness; long‐term safety; real‐world evidence; tralokinumab.

PubMed Disclaimer

Conflict of interest statement

B.E. has received fees for speaking and attending conferences from Janssen‐Cilag Pharma, Stallergenes Greer, Bristol‐Myers Squibb, MEDA Pharma, HAL Allergy, Bencard Allergie, Eli Lilly, Galderma, Novartis, ALK—Abellò, Thermo Fisher Scientific, Pfizer, AbbVie, Leo Pharma, Almirall, La Roche, and L'Oréal. C.B. has been an adviser to and/or received speakers' honoraria from and/or participated in clinical trials for ALK, Almirall, AbbVie, Eli Lilly, Galderma, LEO Pharma, A. Menarini Pharma, Novartis, Pfizer, and Sanofi Genzyme. D.M. has received fees for speaking from Lilly, AbbVie, Almirall, Sanofi, Leo Pharma, Novartis, Janssen‐Cilag, Boehringer Ingelheim, UCB, and Bristol‐Myers Squibb. J.T. has been a consultant or speaker for Almirall, BMS, Eli Lilly, Johnson & Johnson, LEO Pharma, and Novartis, and has received support for congresses from Eli Lilly, Johnson & Johnson, LEO Pharma, and Novartis. B.G. has no conflicts of interest to declare.

Figures

FIGURE 1
FIGURE 1
Change in (a) EASI, (b) IGA, and (c) PP‐NRS from baseline to the most recent assessment. Box plots illustrate the distribution of scores for all patients with available data. The horizontal line within the box indicates the median; the “×” symbol represents the mean; the boxes denote the IQR, and the whiskers extend to the range of values, excluding outliers. Outliers are values outside of 1.5 times the IQR from the upper and lower quartiles, represented by empty circles. “N” numbers are the number of patients with a value at the indicated time. The median (IQR) time to most recent score was 23.5 (18.0–27.0) months for EASI, 18.0 (8.5–24.7) months for IGA, and 23.0 (13.6–26.9) months for PP‐NRS. EASI, Eczema Area and Severity Index; IGA, Investigator Global Assessment; IQR, interquartile range; PP‐NRS, Peak Pruritus Numerical Rating Scale.
See this image and copyright information in PMC

References

    1. De Greef A., Ghislain P. D., Bulinckx A., et al., “Real‐Life Experience of Tralokinumab for the Treatment of Adult Patients With Severe Atopic Dermatitis: A Multicentric Prospective Study,” Clinical Drug Investigation 43, no. 4 (2023): 299–306. - PMC - PubMed
    1. Pereyra‐Rodriguez J. J., Herranz P., Ruiz‐Villaverde R., et al., “Treatment of Severe Atopic Dermatitis With Tralokinumab in Clinical Practice: Short‐Term Effectiveness and Safety Results,” Clinical and Experimental Dermatology 48, no. 9 (2023): 991–997. - PubMed
    1. Ferrucci S., Barei F., Tavecchio S., et al., “Assessment of Patient‐Reported Outcomes at 24 Weeks of Treatment With Tralokinumab for Atopic Dermatitis: A Multicentric Real‐Life Experience,” Journal of Dermatological Treatment 34, no. 1 (2023): 2285243. - PubMed
    1. Pezzolo E., Schena D., Gambardella A., et al., “Survival, Efficacy and Safety of Tralokinumab After 32 and 52 Weeks of Treatment for Moderate‐To‐Severe Atopic Dermatitis in Adults: A Multicentre Real‐World Study,” Journal of the European Academy of Dermatology and Venereology 38, no. 1 (2024): e11–e13. - PubMed
    1. Blauvelt A., Langley R. G., Peris K., et al., “551—Continuous Tralokinumab Treatment Over 4 Years in Adults With Moderate‐To‐Severe Atopic Dermatitis Provides Long‐Term Disease Control,” British Journal of Dermatology 190, no. Supplement_2 (2024): ii48–ii49.

LinkOut - more resources